Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Diabetes Partners Going Their Separate Ways

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

"It's not you; it's me."

That's basically what Bristol-Myers Squibb (NYSE: BMY  ) said to AstraZeneca (NYSE: AZN  ) as it ended their nearly seven-year marriage in diabetes.

In addition to developing drugs as part of the joint venture, the two companies bought an entire company, Amylin Pharmaceuticals, together. Apparently keeping the union together for the kids wasn't an option. The companies seem to have different priorities.

Given the choice, Bristol-Myers would rather sell a billion-dollar cancer drug than a billion-dollar diabetes drug because the margins are much higher with the cancer drug.

AstraZeneca is already heavily focused on primary-care doctors with drugs like its cholesterol drug Crestor. Economies of scale make the lower margins more tolerable.

The deal
AstraZeneca will pay Bristol-Myers $2.7 billion upfront for the full rights to the joint venture, and there's potential for another quick $700 million if AstraZeneca gets regulatory approvals for Forxiga in the first quarter of next year. Bristol-Myers is eligible for another $700 million in undisclosed regulatory- and sales-based milestone payments and royalties on sales through 2015. There's also $225 million for additional assets that may be subsequently transferred to AstraZeneca.

Bristol-Myers' share of the cost to purchase Amylin was a little more than $3 billion, so the company is essentially just getting its money back. The good news is the cash influx will be tax free. The bad news is that it's counting on AstraZeneca's ability to sell the drugs to get those royalties and sales milestones. While that's not as ideal as having control of your own destiny, at least Bristol-Myers has inside knowledge of how AstraZeneca operates.

There goes my prediction?
I've previously pointed out that the Bristol-Myers-Squibb-AstraZeneca diabetes partnership would be a good fit for MannKind's (NASDAQ: MNKD  ) inhaled insulin Afreza. The market for the drug is uncertain because there hasn't been anything like it before, and sharing that risk among two pharmas made a lot of sense. Now, not only would AstraZeneca have to take on all the risk, but I doubt it would want to add a drug while it was in the transition of taking full control of the joint venture.

There are certainly other possible large pharma partners that MannKind could team up with; Eli Lilly (NYSE: LLY  ) and Boehringer Ingelheim have a diabetes joint venture, although it's hard to see Eli Lilly jumping into inhaled insulin after dropping its own program. But clearly today's deal is a net negative for MannKind assuming it has one less potential partner to do a deal with.

Let the predictions begin
Bristol-Myers won't sit on the cash it's getting from AstraZeneca. Dividends and share repurchases were mentioned on the conference call today, but the pharma has been very active with its "string of pearls" strategy of adding drugs through acquisitions. With a more focused specialty pharma, more additions seem like a foregone conclusion.

Who do you think Bristol-Myers could target? Sound off in the comment box below.

Dividend ideas
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks, as a group, handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks, in particular, are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2771793, ~/Articles/ArticleHandler.aspx, 9/29/2016 1:22:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,156.65 -182.59 -1.00%
S&P 500 2,155.38 -15.99 -0.74%
NASD 5,259.25 -59.30 -1.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 1:06 PM
AZN $32.84 Down -0.98 -2.90%
AstraZeneca CAPS Rating: ****
BMY $54.27 Down -0.82 -1.49%
Bristol-Myers Squi… CAPS Rating: ****
LLY $79.55 Down -1.16 -1.44%
Eli Lilly and Co. CAPS Rating: ***
MNKD $0.60 Down -0.01 -1.53%
MannKind CAPS Rating: *